Startseite>>Signaling Pathways>> GPCR/G protein>> Angiotensin Receptor>>Tasosartan (WAY-ANA 756)

Tasosartan (WAY-ANA 756) (Synonyms: WAY-ANA-756)

Katalog-Nr.GC32507

Tasosartan (WAY-ANA 756) ist ein langwirksamer Angiotensin-II (AngII)-Rezeptorantagonist.

Products are for research use only. Not for human use. We do not sell to patients.

Tasosartan (WAY-ANA 756) Chemische Struktur

Cas No.: 145733-36-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
151,00 $
Auf Lager
5mg
138,00 $
Auf Lager
10mg
220,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.

Tasosartan is an orally active nonpeptide AngII antagonist that has demonstrates specific and selective AT1 receptor antagonistic activity in vitro. IC50 for inhibition of specific binding of 125I-AngII to rat adrenal membrane in the absence of proteins in binding buffer is 1.2±0.6 nM[1].

Administration of Tasosartan at doses of 1.0 and 3.0 mg/kg (iv) significantly (p<0.05) attenuates the pressor response to angiotensin-II in rats[2].

[1]. Maillard MP, et al. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. [2]. Elokdah HM, et al. Novel human metabolites of the angiotensin-II antagonist Tasosartan and their pharmacological effects. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71.

Bewertungen

Review for Tasosartan (WAY-ANA 756)

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tasosartan (WAY-ANA 756)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.